Incyte Corporation (INCY) Income Statement Analysis

See more : Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement Analysis – Financial Results

Complete financial analysis of Incyte Corporation (INCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Incyte Corporation, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Dagang NeXchange Berhad (4456.KL) Income Statement Analysis – Financial Results
JSW Infrastructure Limited (JSWINFRA.NS) Income Statement Analysis – Financial Results
Artis Real Estate Investment Trust (AX-PE.TO) Income Statement Analysis – Financial Results
Nansin Co., Ltd. (7399.T) Income Statement Analysis – Financial Results
Zensar Technologies Limited (ZENSARTECH.NS) Income Statement Analysis – Financial Results

Incyte Corporation (INCY)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.incyte.com

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993
Revenue	3.70B	3.39B	2.99B	2.67B	2.16B	1.88B	1.54B	1.11B	753.75M	511.50M	354.95M	297.06M	94.46M	169.88M	9.27M	3.92M	34.44M	27.64M	7.85M	14.15M	47.09M	101.61M	219.26M	194.17M	157.00M	134.80M	88.40M	41.80M	12.20M	200.00K	300.00K
Cost of Revenue	255.00M	207.00M	150.99M	131.33M	114.25M	94.12M	79.48M	58.19M	26.97M	3.00M	630.00K	157.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-34.84M	-24.70M	-17.80M	-10.40M	-6.50M	-2.60M	-900.00K	3.60M
Gross Profit	3.44B	3.19B	2.84B	2.54B	2.04B	1.79B	1.46B	1.05B	726.78M	508.49M	354.32M	296.90M	94.46M	169.88M	9.27M	3.92M	34.44M	27.64M	7.85M	14.15M	47.09M	101.61M	219.26M	229.01M	181.70M	152.60M	98.80M	48.30M	14.80M	1.10M	-3.30M
Gross Profit Ratio	93.10%	93.90%	94.94%	95.08%	94.71%	95.00%	94.83%	94.74%	96.42%	99.41%	99.82%	99.95%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	117.94%	115.73%	113.20%	111.76%	115.55%	121.31%	550.00%	-1,100.00%
Research & Development	1.63B	1.59B	1.46B	2.22B	1.15B	1.20B	1.33B	581.86M	479.51M	347.52M	260.44M	210.39M	178.71M	123.88M	119.44M	146.36M	104.89M	87.60M	95.62M	88.27M	116.25M	152.37M	213.34M	192.56M	146.80M	97.20M	68.90M	40.90M	19.30M	0.00	0.00
General & Administrative	1.16B	1.00B	739.60M	516.90M	453.41M	434.41M	366.41M	303.25M	196.61M	165.77M	109.98M	85.36M	58.22M	32.33M	27.58M	17.07M	15.24M	16.91M	13.01M	74.73M	30.33M	47.15M	70.63M	64.20M	37.20M	25.40M	12.10M	6.80M	0.00	0.00	0.00
Selling & Marketing	0.00	40.00K	-40.00K	22.00K	15.30M	10.60M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.16B	1.00B	739.56M	516.92M	468.71M	434.41M	366.41M	303.25M	196.61M	165.77M	109.98M	85.36M	58.22M	32.33M	27.58M	17.07M	15.24M	16.91M	13.01M	74.73M	30.33M	47.15M	70.63M	64.20M	37.20M	25.40M	12.10M	6.80M	3.90M	12.30M	1.20M
Other Expenses	31.23M	7.97M	37.02M	42.80M	52.18M	31.76M	7.70M	17.42M	0.00	0.00	0.00	0.00	712.00K	-379.00K	2.01M	-227.00K	-407.00K	0.00	0.00	0.00	15.87M	0.00	0.00	34.84M	24.70M	17.80M	10.40M	6.50M	6.50M	13.20M	1.60M
Operating Expenses	2.82B	2.60B	2.23B	2.78B	1.62B	1.63B	1.69B	885.11M	676.13M	513.30M	370.42M	295.75M	237.64M	155.83M	149.03M	163.21M	119.72M	104.51M	108.63M	163.00M	162.44M	199.52M	283.96M	291.60M	208.70M	140.40M	91.40M	54.20M	25.80M	13.20M	1.60M
Cost & Expenses	3.08B	2.80B	2.39B	2.91B	1.74B	1.73B	1.77B	943.30M	703.10M	516.30M	371.05M	295.91M	237.64M	155.83M	149.03M	163.21M	119.72M	104.51M	108.63M	163.00M	162.44M	199.52M	283.96M	256.76M	184.00M	122.60M	81.00M	47.70M	23.20M	12.30M	5.20M
Interest Income	172.35M	39.93M	10.65M	2.17M	1.86M	0.00	17.50M	4.41M	7.09M	3.35M	1.32M	764.00K	462.00K	1.42M	50.00K	5.31M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	2.55M	2.67M	1.91M	2.17M	1.86M	1.54M	6.90M	38.75M	45.60M	46.83M	38.65M	46.06M	43.82M	43.32M	32.13M	5.31M	22.43M	12.53M	12.53M	3.56M	0.00	9.43M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	82.66M	67.86M	57.84M	51.81M	54.53M	54.97M	52.18M	58.43M	44.88M	41.41M	29.21M	29.98M	26.99M	24.49M	16.69M	13.07M	12.96M	7.41M	8.19M	13.91M	17.69M	23.21M	47.67M	34.84M	24.70M	17.80M	10.40M	6.50M	2.60M	900.00K	400.00K
EBITDA	919.43M	599.64M	630.20M	-178.24M	475.66M	209.84M	-253.21M	204.57M	98.04M	39.96M	-14.99M	31.89M	-115.73M	35.96M	-123.08M	-146.22M	-72.32M	-76.86M	-92.59M	-132.06M	-149.30M	-110.52M	-17.03M	-27.75M	-2.30M	30.00M	14.00M	-2.40M	-8.10M	-11.20M	-4.50M
EBITDA Ratio	24.88%	18.60%	20.47%	-8.14%	21.95%	9.95%	-14.23%	15.09%	7.66%	-0.28%	-4.16%	0.64%	-151.59%	10.62%	-1,076.54%	-3,736.80%	-211.16%	-268.72%	-1,185.22%	-949.10%	-103.41%	-36.62%	54.07%	-13.63%	2.10%	26.93%	15.84%	3.11%	-78.69%	-5,950.00%	-1,566.67%
Operating Income	620.53M	579.44M	585.78M	-240.29M	402.01M	129.22M	-243.73M	145.00M	50.65M	-4.80M	-16.10M	1.15M	-143.18M	14.05M	-139.77M	-159.29M	-85.28M	-76.86M	-100.78M	-148.85M	-149.30M	-97.91M	-64.70M	-62.59M	-27.00M	12.20M	7.40M	-5.90M	-11.00M	-12.10M	-4.90M
Operating Income Ratio	16.79%	17.07%	19.62%	-9.01%	18.62%	6.87%	-15.87%	13.11%	6.72%	-0.94%	-4.54%	0.39%	-151.59%	8.27%	-1,508.56%	-4,064.53%	-247.62%	-278.06%	-1,284.53%	-1,052.26%	-317.03%	-96.35%	-29.51%	-32.24%	-17.20%	9.05%	8.37%	-14.11%	-90.16%	-6,050.00%	-1,633.33%
Total Other Income/Expenses	213.69M	-50.32M	-15.33M	31.46M	84.79M	-13.88M	-68.90M	-37.59M	-43.10M	-43.74M	-66.75M	-45.29M	-43.36M	-45.90M	-72.10M	-19.63M	-1.60M	2.70M	-3.13M	-14.36M	-16.69M	2.70M	-122.27M	29.92M	-600.00K	-6.30M	0.00	2.30M	1.10M	700.00K	200.00K
Income Before Tax	834.22M	529.12M	570.44M	-232.22M	486.79M	115.35M	-312.29M	107.40M	7.56M	-48.55M	-82.85M	-44.15M	-186.54M	-31.85M	-211.87M	-178.92M	-86.88M	-74.17M	-103.91M	-163.21M	-165.99M	-135.77M	-186.97M	-32.67M	-27.60M	5.90M	10.90M	-6.60M	-9.80M	-11.40M	-4.70M
Income Before Tax Ratio	22.57%	15.59%	19.10%	-8.71%	22.55%	6.13%	-20.33%	9.71%	1.00%	-9.49%	-23.34%	-14.86%	-197.49%	-18.75%	-2,286.78%	-4,565.45%	-252.27%	-268.30%	-1,324.36%	-1,153.76%	-352.47%	-133.61%	-85.27%	-16.82%	-17.58%	4.38%	12.33%	-15.79%	-80.33%	-5,700.00%	-1,566.67%
Income Tax Expense	236.62M	188.46M	-378.14M	63.48M	39.89M	5.85M	852.00K	3.18M	1.03M	-66.00K	299.00K	174.00K	-26.99M	21.41M	55.41M	19.63M	1.60M	-552.00K	-552.00K	453.00K	477.00K	1.12M	930.00K	205.00K	-800.00K	2.40M	500.00K	900.00K	-900.00K	-600.00K	0.00
Net Income	597.60M	340.66M	948.58M	-295.70M	446.91M	109.49M	-313.14M	104.22M	6.53M	-48.48M	-83.15M	-44.32M	-186.54M	-31.85M	-211.87M	-178.92M	-86.88M	-74.17M	-103.04M	-164.82M	-166.46M	-136.89M	-183.24M	-29.74M	-26.80M	3.50M	10.40M	-6.80M	-10.10M	-11.50M	-4.90M
Net Income Ratio	16.17%	10.04%	31.76%	-11.09%	20.70%	5.82%	-20.38%	9.43%	0.87%	-9.48%	-23.43%	-14.92%	-197.49%	-18.75%	-2,286.78%	-4,565.45%	-252.27%	-268.30%	-1,313.32%	-1,165.11%	-353.48%	-134.71%	-83.57%	-15.31%	-17.07%	2.60%	11.76%	-16.27%	-82.79%	-5,750.00%	-1,633.33%
EPS	2.67	1.53	4.30	-1.36	2.08	0.52	-1.53	0.55	0.04	-0.29	-0.56	-0.34	-1.49	-0.26	-2.06	-1.99	-1.03	-0.89	-1.24	-2.21	-2.33	-2.03	-2.77	-0.47	-0.48	0.07	0.14	-0.17	-0.31	-0.41	-0.19
EPS Diluted	2.65	1.52	4.27	-1.36	2.05	0.51	-1.53	0.54	0.03	-0.29	-0.56	-0.34	-1.49	-0.26	-2.06	-1.99	-1.03	-0.89	-1.24	-2.21	-2.33	-2.03	-2.77	-0.47	-0.48	0.06	0.13	-0.17	-0.31	-0.41	-0.19
Weighted Avg Shares Out	223.63M	222.00M	220.43M	218.07M	214.91M	212.38M	204.58M	187.87M	179.60M	167.18M	148.40M	129.75M	125.36M	121.63M	102.94M	89.79M	84.19M	83.80M	83.32M	74.56M	71.37M	67.40M	66.19M	63.21M	56.28M	53.84M	49.29M	40.00M	33.00M	28.05M	25.58M
Weighted Avg Shares Out (Dil)	225.93M	223.96M	222.07M	218.07M	217.66M	215.64M	204.58M	194.13M	187.30M	167.95M	148.40M	129.75M	125.36M	121.63M	102.94M	89.79M	84.19M	83.80M	83.32M	74.56M	71.37M	67.40M	66.19M	63.21M	56.28M	57.80M	53.08M	40.00M	33.00M	28.05M	25.58M

Doğuş Technology and Doğuş Construction Participate in ConteQ Expo 2024 with Innovative Projects

September 15, 2024businesswire.com

DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, alongside Doğuş Construction, at the Qatar National Convention Center from September 16-18. Both companies will present...

Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

September 14, 2024businesswire.com

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 9, 2024businesswire.com

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

August 29, 2024zacks.com

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

August 19, 2024seekingalpha.com

Incyte Corporation reported positive results achieved from Phase 3 study using Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma. Supplemental Biologics License Application filing for label expansion of Monjuvi for the treatment of patients with relapsed/refractory follicular lymphoma,...

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

August 17, 2024zacks.com

Incyte???s (INCY) late-stage study on tafasitamab for patients with relapsed or refractory follicular lymphoma meets its goal. FDA approves axatilimab for the treatment of chronic graft-versus-host disease.

Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study

August 16, 2024benzinga.com

On Friday, Incyte Corporation INCY released topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi (tafasitamab) and lenalidomide as an add-on to rituximab compared with lenalidomide alone as an add-on to rituximab in patients...